Toxicological studies with a novel synthetic anthracycline, the bis-hydrazone bridged analog of 4-demethoxydaunorubicin (SC-33428).
The toxicological effects of SC-33428, a bis-hydrazone bridged analog of 4-demethoxydaunorubicin were evaluated in rats. The bone marrow depressant effects were more pronounced than those caused by equal doses of doxorubicin, but the cardiotoxic and the nephrotoxic effects were clearly less marked. The concentrations of SC-33428 in serum, heart and kidneys after single and repeated i.p. injections were considerably lower than those reached with doxorubicin. Since the drug is at least as active as doxorubicin in various tumor models, it is likely that it will distinguish itself in the clinic by a broader margin of safety.
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism / Q000633:toxicity*; D001772:Blood Cell Count; D001835:Body Weight / Q000187:drug effects; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000633:toxicity; D004317:Doxorubicin / Q000378:metabolism; D004562:Electrocardiography; D005260:Female; D015255:Idarubicin / Q000031:analogs & derivatives*; D007970:Leukopenia / Q000139:chemically induced; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
D000970:Antineoplastic Agents; C037799:4-demethoxydaunorubicin bis(hydrazone); D004317:Doxorubicin; D015255:Idarubicin; D003630:Daunorubicin